Course Opens
12/22/2023
Credits
1.5
Credit Expires
12/22/2024
The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a challenge to hematologists/oncologists and care teams. As the choice of first-line agent has ramifications for future lines of therapy, hematologists/oncologists need to be able to map out the treatment journey while keeping in mind that therapy resistance or intolerance may arise and that AEs may diminish adherence to therapy.
In this Creative Educational Concepts Enduring Webcast, expert faculty will guide learners through the latest clinical data that informs best practices (including sequencing BTKis), the rationale and support for combination therapies, and the need to factor in the needs and preferences of patients.
At the conclusion of this activity, learners will be able to better:
Supported through independent educational grants from AstraZeneca Pharmaceuticals and Lilly.
Hematologist oncologists and allied oncology health care practitioners (HCPs) including oncology pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs)
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.50 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Oncology Nursing Practice (Scientific Basis/Profession), Treatment Modalities, Diagnosis, Staging & Treatment Planning, Cancer Treatment, Side Effect & Symptom Management, Coordination of Care, Diagnosis, Staging & Treatment Planning, Cancer Treatm
This Application-based activity is approved for 1.50 contact hours ( 0.15 CEUs) of continuing pharmacy credit ( JA0007101-0000-23-015-H01-P ).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Rogers reports the following financial relationships:
Advisory Board: AbbVie Inc.; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LOXO@Lilly; and Pharmacyclics LLC
Consultant: AbbVie Inc. and Pharmacyclics LLC
Research Support: AbbVie Inc.; Genentech, Inc.; and Novartis (paid to institution)
Dr. Davids reports the following financial relationships:
Consultant: AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Meyer Squibb Company; Lilly; Genentech, Inc.; GENMA Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nuvalent; Secura Bio, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapetics, Inc.
Grants: Ascentage Pharma; MEI Pharma, Inc.; and Novartis Pharmaceuticals Corporation
Other financial or material support: UpToDate – authorship royalties
Dr. Faiman reports the following financial relationships:
Consultant: Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc; Karyopharm; Pfizer Inc.; and Sanofi
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Keshia Pitt, PhD (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
WCV-080-122223-90
Call us at 859-260-1717 • info@ceconcepts.com
